A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

MRNA vaccine technology faces growing doubts among state and federal lawmakers. The opposition comes at a critical juncture ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

An Indian origin scientist Vinod Balachandran, MD, in latest data from the phase 1 trial has revealed that an investigational ...

COVID-19 vaccines made by Pfizer and Moderna are both mRNA vaccines, which teach the body to recognize and fight off the ...

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

As viral vaccines are increasingly used to meet global health needs, the pharmaceutical industry is manufacturing larger ...

Developing messenger RNA vaccines such as the Pfizer-BioNTech and Moderna candidates has been fast because scientists were able to start their work before there was a known case of the novel ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...